$TCMD
TACTILE SYSTEMS TECHNOLOGY INC

2021 Q4 Form 10-Q Financial Statement

#000155837021015023 Filed on November 08, 2021

View on sec.gov

Income Statement

Concept 2021 Q4 2021 Q3 2020 Q3
Revenue $61.73M $52.50M $49.09M
YoY Change 4.19% 6.94% -1.05%
Cost Of Revenue $29.61M $15.53M $14.12M
YoY Change -1.67% 9.98% -0.84%
Gross Profit $32.12M $36.97M $34.97M
YoY Change -23.25% 5.71% -1.13%
Gross Profit Margin 52.04% 70.42% 71.24%
Selling, General & Admin $26.14M $36.73M $32.03M
YoY Change 25.91% 14.69% 4.29%
% of Gross Profit 81.37% 99.36% 91.58%
Research & Development $1.774M $1.409M $1.102M
YoY Change 29.49% 27.86% -24.88%
% of Gross Profit 5.52% 3.81% 3.15%
Depreciation & Amortization $1.531M $863.0K $650.0K
YoY Change 121.88% 32.77% -13.33%
% of Gross Profit 4.77% 2.33% 1.86%
Operating Expenses $28.36M $38.34M $33.18M
YoY Change 28.08% 15.54% 3.11%
Operating Profit $3.765M -$1.367M $1.794M
YoY Change -46.15% -176.2% -43.99%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net -$377.0K -$120.0K -$121.0K
YoY Change -131.68% -0.83% -172.89%
Pretax Income $3.388M -$1.487M $1.673M
YoY Change -58.58% -188.88% -50.25%
Income Tax $10.88M $1.900M -$800.0K
% Of Pretax Income 321.22% -47.82%
Net Earnings -$7.495M -$3.355M $2.424M
YoY Change -161.89% -238.41% -0.29%
Net Earnings / Revenue -12.14% -6.39% 4.94%
Basic Earnings Per Share -$0.17 $0.12
Diluted Earnings Per Share -$377.6K -$0.17 $0.12
COMMON SHARES
Basic Shares Outstanding 19.82M 19.79M 19.42M
Diluted Shares Outstanding 19.79M 19.75M

Balance Sheet

Concept 2021 Q4 2021 Q3 2020 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $28.23M $22.40M $42.20M
YoY Change -41.01% -46.92% -5.66%
Cash & Equivalents $28.23M $22.40M $42.20M
Short-Term Investments $0.00 $0.00 $0.00
Other Short-Term Assets $4.141M $3.701M $4.000M
YoY Change 59.27% -7.48% 100.0%
Inventory $19.22M $23.83M $22.42M
Prepaid Expenses
Receivables $49.48M $44.26M $36.03M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $113.5M $106.6M $114.1M
YoY Change -8.14% -6.6% 11.08%
LONG-TERM ASSETS
Property, Plant & Equipment $6.750M $6.458M $7.177M
YoY Change -2.98% -10.02% -4.29%
Goodwill $31.06M $31.06M
YoY Change
Intangibles $54.08M $53.50M $1.671M
YoY Change 3119.11% 3101.68% -67.07%
Long-Term Investments
YoY Change
Other Assets $1.998M $2.082M $1.965M
YoY Change -3.66% 5.95% 39.86%
Total Long-Term Assets $130.7M $142.8M $43.64M
YoY Change 158.99% 227.27% 6.32%
TOTAL ASSETS
Total Short-Term Assets $113.5M $106.6M $114.1M
Total Long-Term Assets $130.7M $142.8M $43.64M
Total Assets $244.3M $249.4M $157.8M
YoY Change 40.31% 58.1% 9.72%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.023M $6.192M $5.053M
YoY Change 19.68% 22.54% -19.65%
Accrued Expenses $5.262M $5.350M $3.582M
YoY Change 18.97% 49.36% -3.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $2.960M $2.210M
YoY Change
Total Short-Term Liabilities $34.46M $31.31M $25.64M
YoY Change 29.0% 22.11% 6.27%
LONG-TERM LIABILITIES
Long-Term Debt $51.79M $52.52M $0.00
YoY Change
Other Long-Term Liabilities $29.76M $33.46M $23.00M
YoY Change 31.68% 45.49% 46.5%
Total Long-Term Liabilities $81.58M $85.98M $22.99M
YoY Change 260.62% 273.99% 46.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $34.46M $31.31M $25.64M
Total Long-Term Liabilities $81.58M $85.98M $22.99M
Total Liabilities $116.0M $117.3M $48.63M
YoY Change 135.2% 141.18% 22.16%
SHAREHOLDERS EQUITY
Retained Earnings $8.245M $15.74M $7.943M
YoY Change -58.89% 98.16% -51.55%
Common Stock $20.00K $20.00K $19.00K
YoY Change 5.26% 5.26% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $128.2M $132.1M $109.1M
YoY Change
Total Liabilities & Shareholders Equity $244.3M $249.4M $157.8M
YoY Change 40.31% 58.1% 9.72%

Cashflow Statement

Concept 2021 Q4 2021 Q3 2020 Q3
OPERATING ACTIVITIES
Net Income -$7.495M -$3.355M $2.424M
YoY Change -161.89% -238.41% -0.29%
Depreciation, Depletion And Amortization $1.531M $863.0K $650.0K
YoY Change 121.88% 32.77% -13.33%
Cash From Operating Activities $5.606M -$1.058M $5.730M
YoY Change 11.23% -118.46% 264.97%
INVESTING ACTIVITIES
Capital Expenditures -$947.0K -$665.0K -$1.020M
YoY Change 89.4% -34.8% -60.31%
Acquisitions
YoY Change
Other Investing Activities $0.00 -$79.83M $5.970M
YoY Change -1437.17% -234.76%
Cash From Investing Activities -$947.0K -$80.49M $4.950M
YoY Change 89.4% -1726.14% -170.71%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 1.169M 54.95M 180.0K
YoY Change 5.32% 30425.56% -10.0%
NET CHANGE
Cash From Operating Activities 5.606M -1.058M 5.730M
Cash From Investing Activities -947.0K -80.49M 4.950M
Cash From Financing Activities 1.169M 54.95M 180.0K
Net Change In Cash 5.828M -26.61M 10.86M
YoY Change 3.15% -344.99% -307.65%
FREE CASH FLOW
Cash From Operating Activities $5.606M -$1.058M $5.730M
Capital Expenditures -$947.0K -$665.0K -$1.020M
Free Cash Flow $6.553M -$393.0K $6.750M
YoY Change 18.29% -105.82% 63.04%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
55416
dei City Area Code
CityAreaCode
612
dei Local Phone Number
LocalPhoneNumber
355-5100
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
TCMD
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Small Business
EntitySmallBusiness
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2021Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset
CY2021Q3 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent
CY2021Q3 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
dei Entity Central Index Key
EntityCentralIndexKey
0001027838
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2021
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2021Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2021Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19797723
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19492718
us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1
CY2020Q4 us-gaap Operating Lease Right Of Use Asset Statement Of Financial Position Extensible List
OperatingLeaseRightOfUseAssetStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseRightOfUseAsset
CY2020Q4 us-gaap Operating Lease Liability Current Statement Of Financial Position Extensible List
OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityCurrent
CY2020Q4 us-gaap Operating Lease Liability Noncurrent Statement Of Financial Position Extensible List
OperatingLeaseLiabilityNoncurrentStatementOfFinancialPositionExtensibleList
http://fasb.org/us-gaap/2021-01-31#OperatingLeaseLiabilityNoncurrent
dei Amendment Flag
AmendmentFlag
false
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2021-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-37799
dei Entity Registrant Name
EntityRegistrantName
Tactile Systems Technology, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Address Address Line1
EntityAddressAddressLine1
3701 Wayzata Blvd, Suite 300
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
41-1801204
dei Entity Shell Company
EntityShellCompany
false
CY2021Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
19823022
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22401000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47855000
CY2021Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
44257000
dei Entity Address City Or Town
EntityAddressCityOrTown
Minneapolis
dei Entity Address State Or Province
EntityAddressStateOrProvince
MN
dei Entity Filer Category
EntityFilerCategory
Large Accelerated Filer
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
43849000
CY2021Q3 us-gaap Net Investment In Lease
NetInvestmentInLease
12385000
CY2020Q4 us-gaap Net Investment In Lease
NetInvestmentInLease
10708000
CY2021Q3 us-gaap Inventory Net
InventoryNet
23830000
CY2020Q4 us-gaap Inventory Net
InventoryNet
18563000
CY2021Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3701000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2638000
CY2021Q3 us-gaap Assets Current
AssetsCurrent
106574000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
123613000
CY2021Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6458000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
6957000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23919000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20132000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
54970000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1680000
CY2021Q3 us-gaap Goodwill
Goodwill
31063000
CY2021Q3 tcmd Medicare Accounts Receivable Non Current
MedicareAccountsReceivableNonCurrent
12422000
CY2020Q4 tcmd Medicare Accounts Receivable Non Current
MedicareAccountsReceivableNonCurrent
9433000
CY2021Q3 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
11907000
CY2020Q4 us-gaap Deferred Income Tax Assets Net
DeferredIncomeTaxAssetsNet
10198000
CY2021Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2082000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
2074000
CY2021Q3 us-gaap Assets Noncurrent
AssetsNoncurrent
142821000
CY2020Q4 us-gaap Assets Noncurrent
AssetsNoncurrent
50474000
CY2021Q3 us-gaap Assets
Assets
249395000
CY2020Q4 us-gaap Assets
Assets
174087000
CY2021Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
6192000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4197000
CY2021Q3 us-gaap Notes Payable Current
NotesPayableCurrent
2210000
CY2021Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10322000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
11588000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5350000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4423000
CY2021Q3 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
1129000
CY2020Q4 us-gaap Accrued Income Taxes Current
AccruedIncomeTaxesCurrent
2658000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2412000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2006000
CY2021Q3 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
3694000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
1842000
CY2021Q3 us-gaap Liabilities Current
LiabilitiesCurrent
31309000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26714000
CY2021Q3 us-gaap Line Of Credit
LineOfCredit
24844000
CY2021Q3 us-gaap Long Term Notes Payable
LongTermNotesPayable
27673000
CY2021Q3 tcmd Earn Out Non Current
EarnOutNonCurrent
6400000
CY2021Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3358000
CY2020Q4 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3235000
CY2021Q3 us-gaap Accrued Income Taxes Noncurrent
AccruedIncomeTaxesNoncurrent
348000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23357000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19388000
CY2021Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
85980000
CY2020Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
22623000
CY2021Q3 us-gaap Liabilities
Liabilities
117289000
CY2020Q4 us-gaap Liabilities
Liabilities
49337000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Value
CommonStockValue
20000
CY2021Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2021Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
50000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19797723
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19492718
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2021Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
116346000
CY2020Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
104675000
CY2021Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
15740000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
20056000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
132106000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
124750000
CY2021Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
249395000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
174087000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52497000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49092000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146329000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
127887000
CY2021Q3 us-gaap Cost Of Revenue
CostOfRevenue
15529000
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
14120000
us-gaap Cost Of Revenue
CostOfRevenue
42926000
us-gaap Cost Of Revenue
CostOfRevenue
36930000
CY2021Q3 us-gaap Gross Profit
GrossProfit
36968000
CY2020Q3 us-gaap Gross Profit
GrossProfit
34972000
us-gaap Gross Profit
GrossProfit
103403000
us-gaap Gross Profit
GrossProfit
90957000
CY2021Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
22231000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
19488000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
61949000
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
59856000
CY2021Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1409000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1102000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3885000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3891000
CY2021Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
14500000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12539000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
42802000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
37682000
CY2021Q3 tcmd Amortization Of Intangible Assets Allocated To Operating Expenses
AmortizationOfIntangibleAssetsAllocatedToOperatingExpenses
195000
CY2020Q3 tcmd Amortization Of Intangible Assets Allocated To Operating Expenses
AmortizationOfIntangibleAssetsAllocatedToOperatingExpenses
49000
tcmd Amortization Of Intangible Assets Allocated To Operating Expenses
AmortizationOfIntangibleAssetsAllocatedToOperatingExpenses
294000
tcmd Amortization Of Intangible Assets Allocated To Operating Expenses
AmortizationOfIntangibleAssetsAllocatedToOperatingExpenses
148000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
38335000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
33178000
us-gaap Operating Expenses
OperatingExpenses
108930000
us-gaap Operating Expenses
OperatingExpenses
101577000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-1367000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
1794000
us-gaap Operating Income Loss
OperatingIncomeLoss
-5527000
us-gaap Operating Income Loss
OperatingIncomeLoss
-10620000
CY2021Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-120000
CY2020Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-121000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-154000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
181000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-1487000
CY2020Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
1673000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-5681000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10439000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1868000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-751000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1365000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2294000
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3355000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2424000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4316000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12733000
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.17
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.12
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.22
us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.66
CY2021Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.17
CY2020Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.12
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.22
us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.66
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19790838
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19415640
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19676749
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19309344
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19790838
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19747365
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19676749
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19309344
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-3355000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
2424000
us-gaap Net Income Loss
NetIncomeLoss
-4316000
us-gaap Net Income Loss
NetIncomeLoss
-12733000
CY2020Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-14000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-21000
CY2020Q3 us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
15000
us-gaap Other Comprehensive Income Loss Tax Portion Attributable To Parent1
OtherComprehensiveIncomeLossTaxPortionAttributableToParent1
5000
CY2020Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-29000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-26000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3355000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2395000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4316000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12759000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
132716000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
2588000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
199000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-42000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3355000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
132106000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
124750000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
7703000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
3584000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-1157000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1542000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4316000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
132106000
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
103385000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
3164000
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
214000
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-39000
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
2395000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
109119000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
112595000
us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
8288000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
762000
us-gaap Adjustments To Additional Paid In Capital Other
AdjustmentsToAdditionalPaidInCapitalOther
-1592000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1825000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12759000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
109119000
us-gaap Profit Loss
ProfitLoss
-4316000
us-gaap Profit Loss
ProfitLoss
-12733000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2150000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2102000
tcmd Amortization Of Premiums And Discounts On Securities Available For Sale
AmortizationOfPremiumsAndDiscountsOnSecuritiesAvailableForSale
-91000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
-1709000
us-gaap Deferred Income Taxes And Tax Credits
DeferredIncomeTaxesAndTaxCredits
3934000
us-gaap Share Based Compensation
ShareBasedCompensation
7703000
us-gaap Share Based Compensation
ShareBasedCompensation
8288000
us-gaap Marketable Securities Gain Loss
MarketableSecuritiesGainLoss
-10000
us-gaap Asset Impairment Charges
AssetImpairmentCharges
4025000
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-7000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
408000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
2589000
tcmd Increase Decrease In Net Investment In Lease
IncreaseDecreaseInNetInvestmentInLease
1677000
tcmd Increase Decrease In Net Investment In Lease
IncreaseDecreaseInNetInvestmentInLease
1304000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3641000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
3538000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
1181000
us-gaap Increase Decrease In Income Taxes Receivable
IncreaseDecreaseInIncomeTaxesReceivable
-773000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1133000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1553000
tcmd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-588000
tcmd Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-509000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
2989000
us-gaap Increase Decrease In Contract With Customer Asset
IncreaseDecreaseInContractWithCustomerAsset
2916000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1995000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
938000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
-1266000
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
766000
tcmd Increase Decrease In Other Accrued Liabilities And Income Taxes Payable
IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable
2902000
tcmd Increase Decrease In Other Accrued Liabilities And Income Taxes Payable
IncreaseDecreaseInOtherAccruedLiabilitiesAndIncomeTaxesPayable
1134000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2975000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-2245000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
22500000
tcmd Payments To Acquire Productive Asset
PaymentsToAcquireProductiveAsset
79829000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1221000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1623000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
187000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
163000
us-gaap Payments To Acquire Other Investments
PaymentsToAcquireOtherInvestments
30000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-81237000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
20684000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
30000000
us-gaap Proceeds From Lines Of Credit
ProceedsFromLinesOfCredit
25000000
us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
211000
tcmd Payment Of Taxes For Net Share Settlement Of Restricted Stock Units
PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits
1157000
tcmd Payment Of Taxes For Net Share Settlement Of Restricted Stock Units
PaymentOfTaxesForNetShareSettlementOfRestrictedStockUnits
1592000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
3584000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
762000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1542000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1825000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58758000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
995000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-25454000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
19434000
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
47855000
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22770000
CY2021Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
22401000
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
42204000
us-gaap Income Taxes Paid
IncomeTaxesPaid
1541000
us-gaap Income Taxes Paid
IncomeTaxesPaid
475000
us-gaap Noncash Or Part Noncash Acquisition Value Of Assets Acquired1
NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1
41000
us-gaap Nature Of Operations
NatureOfOperations
<p style="background-color:#ffffff;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Note 1. Nature of Business and Operations</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Tactile Systems Technology, Inc. (“we,” “us,” and “our”) is the sole manufacturer and distributor of the Flexitouch® and Entre™ systems, medical devices that help control symptoms of lymphedema, a chronic and progressive medical condition.</span> <span style="font-family:'Arial','Helvetica','sans-serif';">We provide these products through our direct sales force for use in the home and sell or rent them through vascular, wound and lymphedema clinics throughout the United States. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">On September 8, 2021, we acquired the assets of the AffloVest respiratory therapy business (“AffloVest Acquisition”) from International Biophysics Corporation (“IBC”), a privately-held company which developed and manufactures AffloVest. AffloVest is a portable, wearable vest that treats patients with chronic respiratory conditions. The device is sold through home medical equipment and durable medical equipment providers throughout the United States. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">We were originally incorporated in Minnesota under the name Tactile Systems Technology, Inc. on January 30, 1995. During 2006, we established a merger corporation and subsequently, on July 21, 2006, merged with and into this merger corporation, resulting in our reincorporation as a Delaware corporation. The resulting corporation assumed the name Tactile Systems Technology, Inc. In September 2013, we began doing business as “Tactile Medical”.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">On August 2, 2016, we closed the initial public offering of our common stock, which resulted in the sale of </span><span style="font-family:'Arial','Helvetica','sans-serif';">4,120,000</span><span style="font-family:'Arial','Helvetica','sans-serif';"> shares of our common stock at a public offering price of </span><span style="font-family:'Arial','Helvetica','sans-serif';">$10.00</span><span style="font-family:'Arial','Helvetica','sans-serif';"> per share. We received net proceeds from the initial public offering of approximately </span><span style="font-family:'Arial','Helvetica','sans-serif';">$35.4</span><span style="font-family:'Arial','Helvetica','sans-serif';"> million, after deducting underwriting discounts and approximately </span><span style="font-family:'Arial','Helvetica','sans-serif';">$2.9</span><span style="font-family:'Arial','Helvetica','sans-serif';"> million of transaction expenses. In connection with the closing of the initial public offering, all of our outstanding redeemable convertible preferred stock automatically converted to common stock on August 2, 2016.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';">Our business is affected by seasonality. In the first quarter of each year, when most patients have started a new insurance year and have not yet met their annual out-of-pocket payment obligations, we experience substantially reduced demand for our products. We typically experience higher revenue in the third and fourth quarters of the year when patients have met their annual insurance deductibles, thereby reducing their out-of-pocket costs for our products, and because patients desire to exhaust their flexible spending accounts at year end. This seasonality applies only to purchases and rentals of our products by patients covered by commercial insurance and is not relevant to Medicare, Medicaid or the Veterans Administration, as those payers either do not have plans that have declining deductibles over the course of the plan year and/or do not have plans that include patient deductibles for purchases or rentals of our products. </span><span style="font-family:'Arial','Helvetica','sans-serif';">Further, seasonality trends in 2021 may be significantly different than in prior years as a result of the COVID-19 pandemic and related impacts</span><span style="font-family:'Arial','Helvetica','sans-serif';">.</span></p>
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 0pt;"><span style="font-family:'Arial','Helvetica','sans-serif';font-style:italic;font-weight:bold;">Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:14pt 0pt 12pt 0pt;"><span style="color:#2b2c2b;font-family:'Arial','Helvetica','sans-serif';">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and to disclose contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.</span></p>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2021Q3 tcmd Goodwill Amortization Period For Tax Purposes
GoodwillAmortizationPeriodForTaxPurposes
P15Y
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
53500000
CY2021Q3 us-gaap Acquired Finite Lived Intangible Assets Weighted Average Useful Life
AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
P12Y3M18D
CY2020Q4 us-gaap Marketable Securities
MarketableSecurities
0
CY2021Q3 us-gaap Marketable Securities
MarketableSecurities
0
tcmd Unrealized Holding Gain Loss On Marketable Securities Arising During Period Before Tax
UnrealizedHoldingGainLossOnMarketableSecuritiesArisingDuringPeriodBeforeTax
0
tcmd Proceeds From Sale Of Marketable Securities
ProceedsFromSaleOfMarketableSecurities
0
CY2020Q4 tcmd Marketable Securities In Unrealized Loss Position
MarketableSecuritiesInUnrealizedLossPosition
0
CY2021Q3 tcmd Marketable Securities In Unrealized Loss Position
MarketableSecuritiesInUnrealizedLossPosition
0
CY2021Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
9607000
CY2020Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
7129000
CY2021Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
14223000
CY2020Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
11434000
CY2021Q3 us-gaap Inventory Net
InventoryNet
23830000
CY2020Q4 us-gaap Inventory Net
InventoryNet
18563000
CY2021Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
45787000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
947000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44840000
CY2021Q3 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
55917000
CY2021Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
947000
CY2021Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
54970000
CY2020Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
1663000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
549000
CY2020Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1114000
CY2020Q4 us-gaap Intangible Assets Gross Excluding Goodwill
IntangibleAssetsGrossExcludingGoodwill
2229000
CY2020Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
549000
CY2020Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
1680000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2020Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
100000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
400000
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
300000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
953000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
3811000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
3781000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
3759000
CY2021Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
3669000
CY2021Q3 tcmd Finite Lived Intangible Asset Expected Amortization After Year Four
FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour
28867000
CY2021Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
44840000
CY2021Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
1341000
CY2021Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1779000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1606000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
634000
CY2021Q3 tcmd In Transit Inventory Accrued Expense
InTransitInventoryAccruedExpense
985000
CY2020Q4 tcmd In Transit Inventory Accrued Expense
InTransitInventoryAccruedExpense
882000
CY2021Q3 tcmd Accrued Travel And Entertainment Current
AccruedTravelAndEntertainmentCurrent
552000
CY2020Q4 tcmd Accrued Travel And Entertainment Current
AccruedTravelAndEntertainmentCurrent
545000
CY2021Q3 tcmd Accrued Sales And Use Tax
AccruedSalesAndUseTax
135000
CY2020Q4 tcmd Accrued Sales And Use Tax
AccruedSalesAndUseTax
67000
CY2021Q3 tcmd Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
109000
CY2020Q4 tcmd Accrued Clinical Studies Expenses Current
AccruedClinicalStudiesExpensesCurrent
193000
CY2021Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
449000
CY2020Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
496000
CY2021Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5350000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4423000
CY2021Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
5117000
CY2020Q2 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4208000
CY2020Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4841000
CY2019Q4 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
3759000
CY2021Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
624000
CY2020Q3 us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
820000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
2080000
us-gaap Standard Product Warranty Accrual Warranties Issued
StandardProductWarrantyAccrualWarrantiesIssued
2097000
CY2021Q3 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
604000
CY2020Q3 us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
514000
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1784000
us-gaap Standard Product Warranty Accrual Payments
StandardProductWarrantyAccrualPayments
1342000
CY2021Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
5137000
CY2020Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4514000
CY2021Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
5137000
CY2020Q3 us-gaap Standard Product Warranty Accrual
StandardProductWarrantyAccrual
4514000
CY2021Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1779000
CY2020Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1443000
CY2021Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1779000
CY2020Q3 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
1443000
CY2021Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3358000
CY2020Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3071000
CY2021Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3358000
CY2020Q3 us-gaap Product Warranty Accrual Noncurrent
ProductWarrantyAccrualNoncurrent
3071000
CY2021Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
5137000
CY2020Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4514000
CY2021Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
5137000
CY2020Q3 us-gaap Product Warranty Accrual
ProductWarrantyAccrual
4514000
CY2021Q3 tcmd Line Of Credit Threshold Contingent Increase In Borrowing Capacity
LineOfCreditThresholdContingentIncreaseInBorrowingCapacity
25000000.0
CY2021Q3 tcmd Credit Agreement Total Aggregate Principal Amount
CreditAgreementTotalAggregatePrincipalAmount
80000000.0
CY2021Q3 us-gaap Line Of Credit
LineOfCredit
25000000.0
CY2021Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
23919000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
20132000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2412000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2006000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23357000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
19388000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
25769000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
21394000
CY2021Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y10M24D
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P9Y4M24D
CY2021Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.044
us-gaap Operating Lease Payments
OperatingLeasePayments
2411000
us-gaap Operating Lease Payments
OperatingLeasePayments
1849000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6146000
us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
6664000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
908000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
3345000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
3274000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3260000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
3359000
CY2021Q3 tcmd Lessee Operating Lease Liability Payments Due After Year Four
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
16653000
CY2021Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
30799000
CY2021Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
5030000
CY2021Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
25769000
CY2021Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2412000
CY2021Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
23357000
CY2021Q3 tcmd Operating Lease Lease Not Yet Commenced Amount
OperatingLeaseLeaseNotYetCommencedAmount
800000
CY2021Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
900000
CY2020Q3 us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
800000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2600000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
2100000
CY2021Q3 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
28400000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2600000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3200000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7700000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8300000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2588000
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3164000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7703000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
8288000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52497000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49092000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146329000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
127887000
CY2021Q3 tcmd Percentage Of Revenue
PercentageOfRevenue
1
CY2020Q3 tcmd Percentage Of Revenue
PercentageOfRevenue
1
tcmd Percentage Of Revenue
PercentageOfRevenue
1
tcmd Percentage Of Revenue
PercentageOfRevenue
1
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52497000
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49092000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
146329000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
127887000
CY2021Q3 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
8037000
CY2020Q3 us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
6519000
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
22114000
us-gaap Sales Type Lease Revenue
SalesTypeLeaseRevenue
18173000
CY2021Q3 us-gaap Cost Of Goods Sold Sales Type Lease
CostOfGoodsSoldSalesTypeLease
2433000
CY2020Q3 us-gaap Cost Of Goods Sold Sales Type Lease
CostOfGoodsSoldSalesTypeLease
2562000
us-gaap Cost Of Goods Sold Sales Type Lease
CostOfGoodsSoldSalesTypeLease
6501000
us-gaap Cost Of Goods Sold Sales Type Lease
CostOfGoodsSoldSalesTypeLease
6062000
CY2021Q3 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
5604000
CY2020Q3 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
3957000
us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
15613000
us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
12111000
CY2021Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
1.26
CY2020Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.55
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
1900000
CY2020Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-800000
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.24
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.17
tcmd Change In Deductibility Of Business Meal Percentage Due To Change In Tax Rate
ChangeInDeductibilityOfBusinessMealPercentageDueToChangeInTaxRate
1
tcmd Change In Deductibility Of Business Meal Percentage Due To Change In Tax Rate
ChangeInDeductibilityOfBusinessMealPercentageDueToChangeInTaxRate
0.50
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-1400000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
2300000
us-gaap Income Tax Reconciliation Tax Contingencies
IncomeTaxReconciliationTaxContingencies
500000
CY2020Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19747365
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19676749
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19309344
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.17
CY2020Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.12
CY2021Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3355000
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
2424000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4316000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12733000
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19790838
CY2020Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19415640
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19676749
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
19309344
CY2020Q3 us-gaap Weighted Average Number Diluted Shares Outstanding Adjustment
WeightedAverageNumberDilutedSharesOutstandingAdjustment
331725
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
19790838
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.22
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.66
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.17
CY2020Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.12
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.22
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.66
CY2021Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1266289
CY2020Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
797765
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1261895
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1367964
CY2021Q3 tcmd Fair Value Transfers Within Three Level Hierarchy
FairValueTransfersWithinThreeLevelHierarchy
0
CY2021Q3 tcmd Fair Value Transfers Within Three Level Hierarchy
FairValueTransfersWithinThreeLevelHierarchy
0
CY2021Q3 tcmd Asset Acquisition Earnout Liability
AssetAcquisitionEarnoutLiability
20000000.0

Files In Submission

Name View Source Status
0001558370-21-015023-index-headers.html Edgar Link pending
0001558370-21-015023-index.html Edgar Link pending
0001558370-21-015023.txt Edgar Link pending
0001558370-21-015023-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
tcmd-20210930.xsd Edgar Link pending
tcmd-20210930x10q.htm Edgar Link pending
tcmd-20210930x10q_htm.xml Edgar Link completed
tcmd-20210930xex31d1.htm Edgar Link pending
tcmd-20210930xex31d2.htm Edgar Link pending
tcmd-20210930xex32d1.htm Edgar Link pending
tcmd-20210930xex32d2.htm Edgar Link pending
tcmd-20210930_cal.xml Edgar Link unprocessable
tcmd-20210930_def.xml Edgar Link unprocessable
tcmd-20210930_lab.xml Edgar Link unprocessable
tcmd-20210930_pre.xml Edgar Link unprocessable